Download a Flyer (Acrobat Reader required)
Additional InformationScope and Methodology
This study focuses on four general product categories, including:
In addition to the four general product categories, a section is dedicated to the potential market, which includes potential prescription to over-the-counter switches, Allegra, Claritin and Zyrtec. Product categories are described in detail and the major market factors in each category are detailed. The report describes the industry, its relationship to various healthcare delivery channels, and trends for the future. The geographic scope of the report is the United States.
The research conducted by Kalorama Information included comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Person-to-person and telephone interviews were the primary method of gathering information. Interviews with over 50 key industry officials, trade association spokespersons, consultants, health care providers, and government personnel were compiled to form the primary basis of information - specifically revenue and market share data - presented in this report.
All market data pertains to the U.S. market at the manufacturers’ level. The base year for data was 2000. Historical data are provided for 1996 through 1999, with forecast data provided for 2001 through 2006. Compound annual growth rates (CAGRs) are provided for the 1996-2000, 2000-2006, and 1996-2006 periods for each industry segment covered.
Largest OTC Market Segment on the Verge of Big Change
New York, October 17, 2001 /PR Newswire —Big changes could be in store for the over-the-counter (OTC) allergy and asthma product market in the near future, according to a new study released today from Kalorama Information and available through MarketResearch.com. Allergy and Asthma products the largest OTC segment in the United States with sales surpassing $1.7 billion last year, could be getting some company on the already crowded drugstore shelves.
The new study, The U.S. Market for Over-the-Counter Allergy and Asthma Products, identifies at least ten likely candidates for Rx-to-OTC switches in this area in the next few years. The most important category—non-sedating antihistamines such as Claritin, Allegra, and Zyrtec—will most likely be available OTC by 2003, according to the study. These allergy medications could grab upwards of 25% of the total market almost immediately after their introduction.
Although the study found modest growth to be the norm in most of the areas covered, remedies for ocular allergies posted respectable growth (near 10%) recently, and the potential OTC candidates likely to hit the market by 2003 are forecast to post healthy growth rates (over 12%) in the subsequent years.
“Modeling OTC markets is notoriously difficult,” notes Steven Heffner, Acquisitions Editor at Kalorama. “There are many more unpredictable variables to take into account than in prescription markets: consumer behavior and brand loyalty, fierce pricing competition especially in the robust generic area, and uncertain reimbursement policies from pharmacy benefits companies. Our analysts looked at consumer and regulatory trends and compiled excellent market information from both the retail unit sales side to the manufacturers’ dollar volume to analyze this complex market.”
More Allergy/Immunology reports by Kalorama Information
Retail Clinics: Consumer Attitudes Results of the 2013 Kalorama Survey by Kalorama Information
Retail Clinics: Consumer Attitudes Results of the 2013 Kalorama Survey - Retail clinics are medical settings located in a retail store. They are ...
What's Next In Vaccines (Malaria, Diabetes, Alzheimer's, Allergies and 30 Other Targets in the 2012-2021 Vaccine Pipeline) by Kalorama Information
Vaccines are one of the most dynamic parts of the pharmaceutical business today but future growth will depend on a considerable amount of potential vaccines ...
The World Market for Over The Counter (OTC) Drugs by Kalorama Information
Over-the-counter (OTC), non-legend, and non-prescription are all adjectives describing drugs that an individual may purchase without a prescription. Many pharmaceutical companies seeking more revenue and ...
The Market for Rx to OTC Switches, 5th Editiion by Kalorama InformationSee all reports like this >>
While many areas of the pharmaceutical industry will suffer from current economic conditions worldwide, sales of over-the-counter drugs are widely anticipated to grow as consumers ...
More United States Allergy/Immunology reports
Pharmaceuticals: Cough, Cold and Allergy (Hay Fever) Remedies in the US by Euromonitor International
Pharmaceuticals: Cough, Cold and Allergy (Hay Fever) Remedies in the USThe relatively mild winter in 2012 provided a sharp juxtaposition to 2013, where the allergy ...
OTC Pharmaceuticals: Cough, Cold and Allergy (Hay Fever) Remedies in the US by Euromonitor International
OTC Pharmaceuticals: Cough, Cold and Allergy (Hay Fever) Remedies in the USThe relatively mild winter in 2012 provided a sharp juxtaposition to 2013, where the ...
Cough & Cold Medicine Manufacturing OTC - Industry Market Research Report - in the US by IBISWorld
Cough & Cold Medicine Manufacturing OTCThe nondiscretionary nature of cough and cold medicine will support stable industry growth, as people consistently contract viruses. Operators will ...
Market Highlights: US Sinusitis – 2014 by Fore PharmaSee all reports like this >>
US Sinusitis Market Highlights – 2014The latest research, 'US Sinusitis Market Highlights – 2014', provides the US sinusitis market analysis, competitive landscape, and sinusitis drug ...
More United States reports
The 2013-2018 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in the United States by Icon Group International, Inc.
The 2013-2018 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in the United StatesThis econometric study covers the latent demand outlook for collagen and (hyaluronic ...
The 2013-2018 Outlook for Relish in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for relish across the states and cities of the United States. Latent demand (in millions of U.S. ...
D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The United States of America by Dun & Bradstreet Inc.See all reports like this >>
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...